PhaseBio Pharmaceuticals — Technical Presentation (November 2021)
43 slides from PhaseBio Pharmaceuticals's technical presentation, Nov 15, 2021
Slide 1: REVERSE-IT Phase 3 Trial: Interim Results Presentation and Roundtable Discussion
REVERSE-IT Phase 3 Trial: Interim Results Presentation and Roundtable Discussion November 15, 2021
Slide 2: Introduction and Corporate Update
Introduction and Corporate Update Jonathan Mow Chief Executive Officer, PhaseBio
Slide 3: Forward-looking statements
This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business str
Slide 4: Pipeline: A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company
Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone Target2 Bentracimab Reversal of Ticagrelor Antiplatelet Activity November 15, 2021 Topline results from Interim Analysis of REVERSE-IT Pemziviptadil Pulmonary Arterial Hypertension (PAH) Mid 2022 Report Phase 2B data P
Slide 5: Why We Are Here Today
Why We Are Here Today 5 Bentracimab Clinical Overview • Discuss P2Y12 inhibitor class, bentracimab and unmet need • Review published bentracimab Phase 1 trial results • Preview unpublished data from Phase 2A trial REVERSE-IT Phase 3 Interim Results • Describe trial overview and goals • Review clinic
Slide 6: Ideal ticagrelor reversal agent criteria
• At the outset of the bentracimab clinical development program, PhaseBio set out criteria for what an ideal ticagrelor reversal agent would look like ⎯ Because it was a theoretical exercise, the bar was set high • Specifically, we aspired to develop a product that was: 1. Safe: patients requiring r
Slide 7: Bentracimab key takeaways
• Bentracimab delivers immediate and sustained restoration of platelet function in both healthy subjects and in patients requiring urgent surgery or invasive procedure, or experiencing uncontrolled major or life- threatening bleeding events • Results from the interim analysis of the Phase 3 REVERSE-
Slide 8: Discussion Panel Participants
Discussion Panel Participants 8 Deepak L. Bhatt, MD, MPH Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School Charles Pollack, MD, MA, FACEP Clinician-Scientist, Department of Emergency Medicine, University of
Slide 9: AHA Analyst Call Agenda
Agenda 9 AHA Analyst Call Agenda: November 15th, 12:30pm ET Presenter Time Introductory Remarks Jonathan Mow, PhaseBio Chief Executive Officer 12:30-12:35 Bentracimab Pivotal Program Overview Dr. John Lee, PhaseBio Chief Medical Officer 12:35-12:40 REVERSE-IT AHA Slide Presentation Dr. Bhatt 12:40-1
Slide 10: Bentracimab Pivotal Program Overview
Bentracimab Pivotal Program Overview John Lee, MD, PhD Chief Medical Officer, PhaseBio
Slide 11: Timelines of Bentracimab Program
bentracimab Timelines of Bentracimab Program 11 2019 2020 2021 2022 2023 Phase 2B: 50-80 year old volunteersPhase 2APhase 1 NEJM FDA Breakthrough Therapy FDA EOP1 EMA PRIME Designation N=200, 150 randomized to receive bentracimab N=150, major bleeding + urgent surgery patients Final N=200 Post -appr
Slide 12: Phase 2B: Reversal of Ticagrelor and Safety
Phase 2B: Reversal of Ticagrelor and Safety Bentracimab achieved primary endpoint of ticagrelor reversal measured by VerifyNow P2Y12 assay • Statistically significant reduction in % inhibition of PRU within 4 hours • Extent of reversal similar to results observed in Phase 1 and 2A studies Safety pro
Slide 13: REVERSE-IT Phase 3 Trial: Results from Prespecified Interim Analysis
REVERSE-IT Phase 3 Trial: Results from Prespecified Interim Analysis Deepak L. Bhatt, MD, MPH Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School
Slide 14: REVERSE-IT: Effect of Bentracimab on Platelet Inhibition and Hemostasis
REVERSE-IT: Effect of Bentracimab on Platelet Inhibition and Hemostasis in Patients on Ticagrelor with Major Bleeding or Requiring Urgent Procedures Deepak L. Bhatt, MD, MPH, Charles V. Pollack, Jr., MD, C. David Mazer, MD, Dominick J. Angiolillo, MD, PhD, Ph. Gabriel Steg, MD, Stefan K. James, MD,
Slide 15: Disclosures
Disclosures Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Bioscien
Slide 16: Ticagrelor: Substantial Data, with Broad Label
Ticagrelor: Substantial Data, with Broad Label • Ticagrelor is an oral P2Y12 inhibitor that is effective (and FDA- approved) in patients with acute coronary syndromes, prior myocardial infarction, high-risk coronary artery disease, transient ischemic attack, and stroke, based on PLATO,1,2 PEGASUS,3,
Slide 17: Ticagrelor: Reversible Mechanism of Action
Ticagrelor: Reversible Mechanism of Action Bhatt DL. Nature Reviews Cardiology. 2009;6:737-38.
Slide 18: Bentracimab: An Intravenous Monoclonal Antibody
Bentracimab: An Intravenous Monoclonal Antibody The P2Y12 receptor is activated by adenosine diphosphate (ADP) (A). On platelets, ticagrelor reversibly binds to the P2Y12 receptor. This induces a conformational change which prevents ADP from signaling through to the P2Y12 receptor, inhibiting platel
Slide 19: Immediate Onset and Sustained Duration of Ticagrelor Reversal
Immediate Onset and Sustained Duration of Ticagrelor Reversal Using Bentracimab (formerly PB2452) P values by timepoint for each cohort Cohort 5min 0.25h 0.5h 1h 2h 3h 6h 8h 10h 12h 16h 20h 7 0.040 0.040 0.131 0.037 0.040 0.019 0.019 0.019 0.152 0.019 0.019 0.224 8 0.019 0.019 0.019 0.019 0.019 0.01
Slide 20: Bentracimab Phase 2A Data
Bentracimab Phase 2A Data Adverse Events PBO (N=6) Bentracimab (N=17) Any AE – no. 13 20 Subjects with AE – no. (%) 5 (83%) 10 (59%) Dry mouth 1 0 Infrequent bowel movements 1 0 Nausea 1 1 Feeling hot (r) 0 2 Infusion site bruising 1 0 Infusion site erythema 1 0 Infusion site extravasation 0 1 Vesse
Slide 21: REVERSE-IT: Enrollment and Study Design
REVERSE-IT: Enrollment and Study Flowchart REVERSE-IT Study Design Multicenter, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab in at least 200 patients who present with uncontrolled major or life-threatening bleeding or who require urg
Slide 22: REVERSE-IT: Endpoints
REVERSE-IT: Endpoints Primary Reversal Endpoint The minimum % inhibition of PRU within 4 hours of bentracimab initiation as assessed by the Verify Now™ PRUTest™ platelet function assay Primary Hemostasis Endpoint (Will be Centrally Adjudicated) Achievement of effective hemostasis within 24 hours aft
Slide 23: REVERSE-IT Study Committees
REVERSE-IT Study Committees Steering Committee Deepak L. Bhatt MD, MPH (Chair), Dominick J. Angiolillo, MD, PhD, Stefan K. James, MD, PhD, Charles V. Pollack, Jr., MA, MD, Ph. Gabriel Steg, MD, Subodh Verma, MD, PhD, Jeffrey I. Weitz, MD Data Safety Monitoring Board W. Frank Peacock, MD, (Chair), De
Slide 24: REVERSE-IT Investigators
REVERSE-IT Investigators REVERSE-IT Investigators Mentor Ahmeti, MD, Denis Angoulvant, MD, PhD, Craig Brown, MD, Warren Cantor, MD, Michael Charles, MD, Marc Claeys, MD, PhD, Francesco Franchi, MD, Alex Gregory, MD, Zafir Hawa, MD, Michael Heffernan, MD, John Kotter, MD, Gilles Lemesle, MD, PhD, Dav
Slide 25: REVERSE-IT: Enrollment and Study Flowchart
REVERSE-IT: Enrollment and Study Flowchart
Slide 26: REVERSE-IT: Baseline Characteristics
REVERSE-IT: Baseline Characteristics
Slide 27: REVERSE-IT: Platelet Function Tests, Percent Inhibition of PRU
REVERSE-IT: Platelet Function Tests Percent Inhibition of PRU PRU Analysis of Reversal Ticagrelor Reversal with VerifyNow PRU. Ticagrelor reversal is shown as a reduction in % inhibition of PRU or PRI and as an increase in PRU or platelet reactivity index at multiple timepoints post-treatment. Shown
Slide 28: REVERSE-IT: Platelet Function Tests, PRI Analysis
REVERSE-IT: Platelet Function Tests PRI analysis of ReversalPercent Inhibition of PRI Ticagrelor Reversal with VASP platelet reactivity index (PRI). Comparison of % inhibition of platelet reactivity index pre- treatment and the minimum % inhibition of platelet reactivity index within 4 hours of init
Slide 29: REVERSE-IT: Reversal in Surgical and Bleeding Patients
REVERSE-IT: Reversal in Surgical and Bleeding Pts PRU analysis in surgical and bleeding patients PRI analysis in surgical and bleeding patients Ticagrelor Reversal in Bleeding and Surgical Patients. Multiple platelet function assays were used to measure extent of ticagrelor reversal in bleeding and
Slide 30: REVERSE-IT: Subgroups Forest Plot for % Inhibition of PRU
REVERSE-IT: Platelet Function Tests Subgroups Forest Plot for % Inhibition of PRU Prespecified Subgroup Analyses of the Primary Reversal Endpoint. The primary reversal endpoint was the minimum % inhibition of PRU within 4 hours of study drug initiation compared to pre-treatment % inhibition of PRU.
Slide 31: Enrollment of Urgent Surgical and Major Bleeding Patients
Enrollment of Urgent Surgical and Major Bleeding Patients in REVERSE-IT Enrolled Urgent Surgical and Major Bleeding Patients
Slide 32: REVERSE-IT: Adjudicated Surgical Hemostasis
REVERSE-IT: Adjudicated Surgical Hemostasis Adjudicated and Investigator-Reported Surgical Outcomes
Slide 33: REVERSE-IT: Adjudicated Bleeding Hemostasis
REVERSE-IT: Adjudicated Bleeding Hemostasis Adjudicated and Investigator-Reported Bleeding Outcomes
Slide 34: REVERSE-IT: Adjudicated Hemostasis Subgroups
REVERSE-IT: Adjudicated Hemostasis Subgroups Forest Plot for Effective Hemostasis (Adjudicated) Prespecified Subgroup Analyses of the Primary Hemostasis Endpoint. The primary hemostasis endpoint was the proportion of patients adjudicated to have achieved effective hemostasis compared to 50% expected
Slide 35: REVERSE-IT: No Platelet Rebound Activity
REVERSE-IT: No Platelet Rebound Activity P-selectin in surgical and bleeding patients Mean platelet volume in surgical and bleeding patients Effect of Bentracimab Treatment on P-Selectin and Mean Platelet Volume (MPV). Soluble P-selectin and MPV were measured pre-dose and at multiple timepoints post
Slide 36: REVERSE-IT: Adjudicated Thrombotic Events
REVERSE-IT: Adjudicated Thrombotic Events Adjudicated Thrombotic Events Occurring Post-Reversal
Slide 37: Limitations
Limitations • There was no control arm, as it was felt to be challenging to randomize to a placebo (as with the NOAC reversal trials). • The majority of surgical patients underwent cardiac surgery, though no reason to think the results don’t apply to other surgeries and invasive procedures. • The nu
Slide 38: Conclusion
Conclusion • Using the VerifyNow and VASP assays in ticagrelor-treated patients undergoing invasive procedures or with major bleeding, bentracimab, a specific reversal agent for ticagrelor, provided immediate and sustained reversal of ticagrelor’s antiplatelet effects. • Rates of effective hemostasi
Slide 39: Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery Deepak L. Bhatt, MD, MPH, Charles V. Pollack, Jr., MD, C. David Mazer, MD, Dominick J. Angiolillo, MD, PhD, Ph. Gabriel Steg, MD, Stefan K. James, MD, PhD, Jeffrey I. Weitz, MD, Rohit Ramnath, PhD, Susan E. Arnold, PhD, Michae
Slide 40: Thank You!
TICAGRELOR IN STABLE CAD AND T2D TREATED WITH ASA www.brighamandwomens.org/heart Deepak L. Bhatt, MD, MPH Executive Director, Interventional Cardiovascular Programs, BWH Heart & Vascular Center; Professor of Medicine, Harvard Medical School Email: [email protected] Twitter: @DLBhattMD Thank
Slide 41: REVERSE-IT Prespecified Interim Results Panel Discussion
REVERSE-IT Phase 3 Trial: Prespecified Interim Results Panel Discussion Deepak L. Bhatt, MD, MPH John Lee, MD, PhD Charles Pollack, MD, MA Ph. Gabriel Steg, MD
Slide 42: Closing Remarks and Q&A
Closing Remarks and Q&A Jonathan Mow Chief Executive Officer, PhaseBio
Slide 43: PhaseBio Thank you!
PhaseBio Thank you!
PhaseBio Pharmaceuticals — Technical Presentation (November 2021) on 6ix